TERT promoter and TP53 mutations are the most frequent and distinct mutations in ATCs, while common driver mutations in thyroid cancers such as BRAF and RAS (including NRAS, HRAS, and KRAS) are shared between ATCs and their precedent, well-differentiated thyroid cancer [8]. This evidence concerns the gene KRAS and Ehlers-Danlos syndrome, musculocontractural type.